KPTI - NASDAQ
Karyopharm Therapeutics Inc.
$9.23
+2.3%Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
At a Glance
Live SnapshotKaryopharm Therapeutics Inc. Management Team
Mr. James Accumanno J.D.
Chief Compliance Officer
Dr. Mansoor Raza Mirza M.D.
Clinical Consultant, Member of Scientific Advisory Board & Independent Director
Compensation
$150,000
Dr. Sharon Shacham M.B.A., Ph.D.
Co-Founder & Chairman of Scientific Advisory Board
Compensation
$1,404,313
Ms. Lori A. Macomber CPA
EVice President, Chief Financial Officer & Treasurer
Ms. Sohanya Cheng M.B.A.
Executive Vice President, Chief Commercial Officer & Head of Business Development
Compensation
$779,035
Dr. Reshma Rangwala M.D., Ph.D.
Executive Vice President, Chief Medical Officer & Head of Research
Compensation
$808,650
Mr. Richard A. Paulson M.B.A.
President, Chief Executive Officer & Director
Compensation
$1,214,737
Mr. Brendan Twohig Strong
SVice President of Investor Relations & Corporate Communications
Mr. Michael J. Mano J.D.
Senior Vice President, General Counsel & Secretary
Compensation
$625,075
Ms. Kristin Abate
Vice President, Chief Accounting Officer & Assistant Treasurer
Karyopharm Therapeutics Inc. Insider Positioning
During the last 12 months, insiders have sold $364K worth of KPTI shares, with no buying activity reported.
3 Months
0
0.00
4.1K
38.75K
-39K
-$39K
3-6 Months
0
0.00
33.0K
303.91K
-304K
-$304K
6-9 Months
0
0.00
3.0K
19.30K
-19K
-$19K
9-12 Months
0
0.00
441
1.87K
-2K
-$2K
Top Buyers
No buying activity
Top Sellers
Paulson Richard A.
Director, Officer: President And Ceo
$145K
Poulton Stuart
Officer: Evp, Chief Development Officer
$58K
Rangwala Reshma
Officer: Evp & Chief Medical Officer
$58K
Cheng Sohanya Roshan
Officer: Evp & Chief Commercial Officer
$48K
Mano Michael
Officer: Evp, Clo&Secretary
$37K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $364K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
KPTI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 13, 2026 | April 13, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | January 09, 2026 | February 18, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 14, 2025 | May 28, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | December 16, 2024 | January 30, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 19, 2024 | May 29, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 11, 2023 | April 11, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 08, 2022 | May 19, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 07, 2021 | May 21, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 09, 2020 | May 21, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 19, 2019 | June 06, 2019 | 2019 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.